

MERCK LIMITED



Regd. Office: Shivsagar Estate 'A', Dr. Annie Besant Road, Worli, Mumbai - 400018

AUDITED FINANCIAL RESULTS FOR YEAR ENDED 31ST DECEMBER, 2013

(Rs. in Lakhs)

(Rs. in Lakhs)

Particulars	3 months ended 31/12/2013 Audited	Preceding 3 months ended 30/09/2013 Unaudited	Corresponding 3 months ended 31/12/2012 in the previous year Audited	Year to date figures for the current year ended 31/12/2013 Audited	Previous year ended 31/12/2012 Audited
1. Income from operations					
a) Net Sales/income from operations (Net of excise duty)	19,420.11	20,181.88	16,117.94	77,296.24	65,807.05
b) Other operating income	804.80	565.43	638.70	2,481.56	2,920.90
Total income from operations (net)	20,224.91	20,747.31	16,756.64	79,777.80	68,727.95
2. Expenses					
a) Cost of materials consumed	4,425.06	6,159.22	4,352.78	24,030.64	17,943.63
b) Purchases of stock-in-trade	4,289.41	3,941.53	3,068.71	15,184.45	11,608.69
c) Changes in inventories of finished goods, work-in-progress and stock in trade	1,206.01	(651.28)	(126.75)	(2,914.64)	349.14
d) Employee benefits expense	2,541.82	2,619.93	1,747.57	10,096.30	8,530.07
e) Depreciation and amortisation expense	285.68	246.72	240.42	1,006.57	889.77
f) Other expenses	6,239.55	6,500.05	5,180.00	25,694.51	19,747.21
Total expenses	18,987.53	18,816.17	14,462.73	73,097.83	59,068.51
3. Profit from operations before other income, finance costs and exceptional Items (1-2)	1,237.38	1,931.14	2,293.91	6,679.97	9,659.44
4. Other Income	533.24	513.49	588.23	2,144.81	2,019.56
5. Profit from ordinary activities before finance costs and exceptional Items (3+4)	1,770.62	2,444.63	2,882.14	8,824.78	11,679.00
6. Finance Cost	-	-	-	-	-
7. Profit from ordinary activities after finance costs and before exceptional Items (5-6)	1,770.62	2,444.63	2,882.14	8,824.78	11,679.00
8. Exceptional items	-	-	-	-	-
9. Profit from ordinary activities before tax (7+8)	1,770.62	2,444.63	2,882.14	8,824.78	11,679.00
10. Tax expense *	826.44	867.14	876.86	3,237.17	3,838.86
11. Net Profit from Ordinary Activities after tax (9-10)	944.18	1,577.49	2,005.28	5,587.61	7,840.14
12. Extraordinary items (net of tax expense)	-	-	-	-	-
13. Net Profit for the period (11±12)	944.18	1,577.49	2,005.28	5,587.61	7,840.14
14. Paid-up equity share capital (Face Value Rs 10/-)	1,659.94	1,659.94	1,659.94	1,659.94	1,659.94
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	50,643.06	46,706.19
16.i Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):					
(a) Basic	5.69	9.50	12.08	33.66	47.23
(b) Diluted	5.69	9.50	12.08	33.66	47.23
16.ii Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):					
(a) Basic	5.69	9.50	12.08	33.66	47.23
(b) Diluted	5.69	9.50	12.08	33.66	47.23
A PARTICULARS OF SHAREHOLDING					
1 Public shareholding					
- Number of shares	8,000,158	8,000,158	8,000,158	8,000,158	8,000,158
- Percentage of shareholding	48.2	48.2	48.2	48.2	48.2
2 Promoters and Promoter Group Shareholding					
(a) Pledged/ Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	-	-	-	-	-
- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-
(b) Non-encumbered					
- Number of shares	8,599,224	8,599,224	8,599,224	8,599,224	8,599,224
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100	100	100	100	100
- Percentage of shares (as a % of the total share capital of the company)	51.8	51.8	51.8	51.8	51.8
* Tax expense consists of:					
Current Tax	680.00	860.00	890.00	3,200.00	3,850.00
Deferred Tax	146.44	7.14	(13.14)	37.17	(11.14)

Segment Wise Revenue, Result and Capital Employed					
Particulars	3 months ended 31/12/2013 Audited	Preceding 3 months ended 30/09/2013 Unaudited	Corresponding 3 months ended 31/12/2012 in the previous year Audited	Year to date figures for the current year ended 31/12/2013 Audited	Previous year ended 31/12/2012 Audited
1. Segment Revenue					
a) Pharmaceuticals	13,954.71	14,747.27	10,912.35	54,621.76	45,733.52
b) Chemicals	6,319.44	6,443.28	6,277.68	26,633.49	24,639.33
Total	20,274.15	21,190.55	17,190.03	81,255.25	70,372.85
Less : Inter segment revenue	49.24	443.24	433.39	1,477.45	1,644.90
Net Sales and Other Operating Income	20,224.91	20,747.31	16,756.64	79,777.80	68,727.95
2. Segment Results (Profit before Tax and Interest from each segment)					
a) Pharmaceuticals	1,031.95	1,734.42	1,586.01	5,151.91	6,554.67
b) Chemicals	501.48	350.66	763.03	2,331.26	3,199.03
Total	1,533.43	2,085.08	2,349.04	7,483.17	9,753.70
Less :					
Other un-allocable expenditure net off un-allocable Income	(237.19)	(359.55)	(533.10)	(1,341.61)	(1,925.30)
Total Profit before Tax	1,770.62	2,444.63	2,882.14	8,824.78	11,679.00
3. Capital Employed					
a) Pharmaceuticals	12,597.35	12,904.82	7,864.43	12,597.35	7,864.43
b) Chemicals	15,459.30	15,600.36	13,946.60	15,459.30	13,946.60
c) Unallocated	24,246.35	24,504.38	26,555.10	24,246.35	26,555.10
Total	52,303.00	53,009.56	48,366.13	52,303.00	48,366.13

Statement of Assets and Liabilities		
Particulars	As at Current year end 31.12.2013	As at Previous year end 31.12.2012
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share capital	1,659.94	1,659.94
(b) Reserves and surplus	50,643.06	46,706.19
Sub-total-Shareholders' funds	52,303.00	48,366.13
2 Non- current liabilities		
(a) Deferred tax liabilities(net)	109.66	72.49
(b) Long-term provisions	1,216.63	1,281.55
Sub-total-Non-current liabilities	1,326.29	1,354.04
3 Current liabilities		
(a) Trade payables	3,681.03	3,970.51
(b) Other current liabilities	4,349.05	3,827.31
(c) Short-term provisions	3,201.90	1,909.49
Sub-total-Current liabilities	11,231.98	9,707.31
TOTAL- EQUITY AND LIABILITIES	64,861.27	59,427.48
B ASSETS		
1 Non-current assets		
(a) Fixed assets	9,406.00	7,690.23
(b) Long-term loans and advances	6,783.25	5,887.54
(c) Other non-current assets	865.10	-
Sub-total - Non-current assets	17,054.35	13,577.77
2 Current assets		
(a) Current investments	2,429.07	2,363.83
(b) Inventories	15,182.26	13,096.27
(c) Trade receivables	8,411.67	6,442.00
(d) Cash and cash equivalents	18,769.22	19,298.44
(e) Short-term loans and advances	2,316.20	3,951.91
(f) Other current assets	698.50	697.26
Sub-total - Current assets	47,806.92	45,849.71
TOTAL - ASSETS	64,861.27	59,427.48

Notes :-

- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 31st January, 2014. The statutory auditors have expressed an unqualified opinion. The audit report has been filed with stock exchange and is available on the company's website.
- Figures for the previous quarter/year have been re-grouped/re-arranged wherever necessary.
- The figures of last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the third quarter of the current financial year and previous financial year.
- The Board of Directors at its meeting held on 31st January, 2014 recommended a dividend of Rs. 8.50 per share for the year ended 31st December 2013.

Place : Mumbai
Date : 31st January, 2014
Please visit us at our website www.merck.co.in

For MERCK LIMITED

Sd/-

Dr. Claus-Dieter Boedecker
MANAGING DIRECTOR

B S R & Co. LLP

Chartered Accountants

1st Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalakshmi
Mumbai - 400 011
India

Telephone +91 22 3989 6000
Fax +91 22 3090 2511

Auditors' Report on financial results of Merck Limited pursuant to Clause 41 of Listing Agreement

To Board of Directors of Merck Limited

We have audited the accompanying annual financial results of Merck Limited ('the Company') for the year ended 31 December 2013, attached herewith, being submitted by the Company pursuant to the requirement of clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. Attention is drawn to the fact that the figures for the quarter ended 31 December 2013 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

These financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results upto the end of the third quarter which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of the annual financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 which as per a clarification issued by the Ministry of Corporate Affairs continue to apply under section 133 of the Companies Act, 2013 (which has superseded section 211(3C) of the Companies Act, 1956 w.e.f. 12 September 2013) and other accounting principles generally accepted in India and in compliance with Clause 41 of the Listing Agreement.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the year ended 31 December 2013



**Auditors' Report on financial results of Merck Limited pursuant to
Clause 41 of Listing Agreement (*Continued*)**

Merck Limited

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the Company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For **BSR & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W



Sadashiv Shetty
Partner

Membership No: 048648

Mumbai
31 January 2014